Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction Insights From Get With the Guidelines-Heart Failure (GWTG-HF) JACC-HEART FAILURE Luo, N., Fonarow, G. C., Lippmann, S. J., Mi, X., Heidenreich, P. A., Yancy, C. W., Greiner, M. A., Hammill, B. G., Hardy, N. C., Turner, S. J., Laskey, W. K., Curtis, L. H., Hernandez, A. F., Mentz, R. J., O'Brien, E. C. 2017; 5 (4): 305-309


The aim of this study was to assess the prevalence and variation in angiotensin receptor/neprilysin inhibitor (ARNI) prescription among a real-world population with heart failure with reduced ejection fraction (HFrEF).The U.S. Food and Drug Administration approved sacubitril/valsartan for patients with HFrEF in July 2015. Little is known about the early patterns of use of this novel therapy.The study included patients discharged alive from hospitals in Get With the Guidelines-Heart Failure (GWTG-HF), a registry of hospitalized patients with heart failure, between July 2015 and June 2016 who had documentation of whether ARNIs were prescribed at discharge. Patient and hospital characteristics were compared among patients with HFrEF (ejection fraction =40%) with and without ARNI prescription at discharge, excluding those with documented contraindications to ARNIs. To evaluate hospital variation, hospitals with at least 10 eligible hospitalizations during the study period were assessed.Of 21,078 patients hospitalized with HFrEF during the study period, 495 (2.3%) were prescribed ARNIs at discharge. Patients prescribed ARNIs were younger (median age 65 years vs. 70 years; p < 0.001), had lower ejection fractions (median 23% vs. 25%; p < 0.001), and had higher use of aldosterone antagonists (45% vs. 31%; p < 0.001) at discharge. At the 241 participating hospitals with 10 or more eligible admissions, 125 (52%) reported no discharge prescriptions of ARNIs.Approximately 2.3% of patients hospitalized for HFrEF in a national registry were prescribed ARNI therapy in the first 12 months following Food and Drug Administration approval. Further study is needed to identify and overcome barriers to implementing new evidence into practice, such as ARNI use among eligible patients with HFrEF.

View details for DOI 10.1016/j.jchf.2016.12.018

View details for Web of Science ID 000398335800010

View details for PubMedID 28359417